Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNGX

SNGX - Soligenix Inc Stock Price, Fair Value and News

$1.39+0.05 (+3.73%)
Market Closed

41/100

SNGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

41/100

SNGX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.26

Target 3M

$1.35

Target 6M

$1.32

SNGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNGX Price Action

Last 7 days

-0.7%

Last 30 days

-1.4%

Last 90 days

-7.9%

Trailing 12 Months

-42.3%

SNGX RSI Chart

SNGX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNGX Valuation

Market Cap

14.0M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

116.6

EV/EBITDA

-0.38

Price/Free Cashflow

-1.09

SNGX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.26

Target 3M

$1.35

Target 6M

$1.32

SNGX Fundamentals

SNGX Revenue

Revenue (TTM)

119.4K

SNGX Earnings

Earnings (TTM)

-11.2M

Earnings Growth (Yr)

-47.2%

Earnings Growth (Qtr)

6.33%

SNGX Profitability

EBT Margin

-9117.43%

Return on Equity

-147.03%

Return on Assets

-98.92%

Free Cashflow Yield

-91.57%

SNGX Investor Care

Shares Dilution (1Y)

301.92%

Diluted EPS (TTM)

-2.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024699.2K494.6K364.2K119.4K
20231.0M996.3K960.6K839.4K
2022864.7K878.6K858.5K948.9K
20211.6M1.3M869.4K824.3K
20204.4M3.4M2.7M2.4M
20195.3M5.1M5.0M4.6M
20185.2M6.0M5.5M5.2M
201708.1M7.3M5.4M
20160000
20150000
20143.2M4.0M6.5M1.5M
20133.2M3.2M2.8M3.2M
20126.1M6.4M2.3M0
20113.0M4.1M5.1M6.2M
20100001.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Soligenix Inc

SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
 CEO
 WEBSITEsoligenix.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES13

Soligenix Inc Frequently Asked Questions

SNGX is the stock ticker symbol of Soligenix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Soligenix Inc is 14.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SNGX's fair value in chart for subscribers.

The fair value guage provides a quick view whether SNGX is over valued or under valued. Whether Soligenix Inc is cheap or expensive depends on the assumptions which impact Soligenix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNGX.

As of Wed Jan 28 2026, SNGX's PE ratio (Price to Earnings) is -1.25 and Price to Sales (PS) ratio is 116.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNGX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Soligenix Inc has provided -0.519 (multiply by 100 for percentage) rate of return.